Zevra Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with rare diseases and complex disorders
The company leverages advanced scientific research to address unmet medical needs, particularly in the areas of neurological and metabolic conditions. Through its commitment to cutting-edge innovation and patient-centered solutions, Zevra Therapeutics aims to improve the quality of life for individuals affected by challenging health conditions, fostering hope and enhancing treatment options in the biotech landscape.
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic Metabolic Diseases Advisory Committee.
FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare disease portfolio. Key decisions and market opportunities ahead in 2024.
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.
Companies Reporting Before The Bell • Universal Stainless (NASDAQUSAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
